Organisation paid for research Program year 2023 Source: CMS Open Payments

Apf Research

Neither a doctor nor a teaching hospital

Research payments

$744,282

14 payments

Through program year 2023, Apf Research is reported as receiving $744,282 in research payments, across 14 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$97,782	1
2022	Research	$178,576	1
2021	Research	$412,076	1
2019	Research	$55,848	11

Breakdown

Who paid Research payments · program years 2019–2023

AstraZeneca UK Limited $412,076 1 payment
AstraZeneca Pharmaceuticals LP $276,358 2 payments
Allergan Inc. $55,848 11 payments

Studies the money was for Research payments · program years 2019–2023

A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $688,434 3 payments
12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $36,519 7 payments
A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $11,723 1 payment
A 46-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Longterm Study With A 6-Week Randomized-Withdrawal Period to Evaluate the Safety and $7,607 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.